Asunto(s)
Vacunas contra la Malaria/historia , Vacunas Sintéticas/historia , Niño , Preescolar , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Lactante , Malaria/historia , Malaria/prevención & control , Vacunas contra la Malaria/uso terapéutico , Malaria Falciparum/prevención & control , Mozambique , Plasmodium falciparum , Ensayos Clínicos Controlados Aleatorios como Asunto/historia , Vacunas Sintéticas/uso terapéuticoRESUMEN
Although viruses and bacteria have been known as agents of diseases since 1546, 250 years went by until the first vaccines against these pathogens were developed (1796 and 1800s). In contrast, Malaria, which is a protozoan-neglected disease, has been known since the 5th century BCE and, despite 2,500 years having passed since then, no human vaccine has yet been licensed for Malaria. Additionally, no modern human vaccine is currently licensed against Visceral or Cutaneous leishmaniasis. Vaccination against Malaria evolved from the inoculation of irradiated sporozoites through the bite of Anopheles mosquitoes in 1930's, which failed to give protection, to the use of controlled human Malaria infection (CHMI) provoked by live sporozoites of Plasmodium falciparum and curtailed with specific chemotherapy since 1940's. Although the use of CHMI for vaccination was relatively efficacious, it has some ethical limitations and was substituted by the use of injected recombinant vaccines expressing the main antigens of the parasite cycle, starting in 1980. Pre-erythrocytic (PEV), Blood stage (BSV), transmission-blocking (TBV), antitoxic (AT), and pregnancy-associated Malaria vaccines are under development. Currently, the RTS,S-PEV vaccine, based on the circumsporozoite protein, is the only one that has arrived at the Phase III trial stage. The "R" stands for the central repeat region of Plasmodium (P.) falciparum circumsporozoite protein (CSP); the "T" for the T-cell epitopes of the CSP; and the "S" for hepatitis B surface antigen (HBsAg). In Africa, this latter vaccine achieved only 36.7% vaccine efficacy (VE) in 5-7 years old children and was associated with an increase in clinical cases in one assay. Therefore, in spite of 35 years of research, there is no currently licensed vaccine against Malaria. In contrast, more progress has been achieved regarding prevention of leishmaniasis by vaccine, which also started with the use of live vaccines. For ethical reasons, these were substituted by second-generation subunit or recombinant DNA and protein vaccines. Currently, there is one live vaccine for humans licensed in Uzbekistan, and four licensed veterinary vaccines against visceral leishmaniasis: Leishmune® (76-80% VE) and CaniLeish® (68.4% VE), which give protection against strong endpoints (severe disease and deaths under natural conditions), and, under less severe endpoints (parasitologically and PCR-positive cases), Leishtec® developed 71.4% VE in a low infective pressure area but only 35.7% VE and transient protection in a high infective pressure area, while Letifend® promoted 72% VE. A human recombinant vaccine based on the Nucleoside hydrolase NH36 of Leishmania (L.) donovani, the main antigen of the Leishmune® vaccine, and the sterol 24-c-methyltransferase (SMT) from L. (L.) infantum has reached the Phase I clinical trial phase but has not yet been licensed against the disease. This review describes the history of vaccine development and is focused on licensed formulations that have been used in preventive medicine. Special attention has been given to the delay in the development and licensing of human vaccines against Protozoan infections, which show high incidence worldwide and still remain severe threats to Public Health.
Asunto(s)
Leishmania donovani/inmunología , Vacunas contra la Leishmaniasis/historia , Leishmaniasis Visceral/prevención & control , Concesión de Licencias/historia , Vacunas contra la Malaria/historia , Malaria Falciparum/prevención & control , Vacunación Masiva/historia , Plasmodium falciparum/inmunología , Adulto , Animales , Niño , Preescolar , Femenino , Historia del Siglo XVII , Historia del Siglo XVIII , Historia del Siglo XIX , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Vacunas contra la Leishmaniasis/inmunología , Leishmaniasis Visceral/parasitología , Leishmaniasis Visceral/veterinaria , Vacunas contra la Malaria/inmunología , Malaria Falciparum/parasitología , Vacunación Masiva/métodos , Embarazo , Vacunas Atenuadas/historia , Vacunas Atenuadas/inmunología , Vacunas Vivas no Atenuadas/historia , Vacunas Vivas no Atenuadas/inmunología , Vacunas Sintéticas/historia , Vacunas Sintéticas/inmunologíaRESUMEN
Early trials of killed, whole-cell typhoid vaccine indicated a paradoxical, positive effect on malaria infections. British soldiers in India in 1898 reported > 90% decrease in malaria recurrences after receiving an investigational typhoid vaccine despite no intention or expectation to observe such an outcome. In the 1940s, multiple doses of intravenous typhoid vaccine appeared to control parasitemia and limit reinfection in three syphilis patients purposefully infected with Plasmodium vivax. Several modern vaccines (against human papillomavirus, hepatitis B virus, and malaria) use a detoxified lipid A derived from Salmonella as an immune adjuvant. Early typhoid vaccines could have plausibly functioned as an innate immune stimulus, leading to some protection against malaria.
Asunto(s)
Vacunas contra la Malaria/historia , Vacunas contra la Malaria/uso terapéutico , Malaria/prevención & control , Vacunas Tifoides-Paratifoides/administración & dosificación , Historia del Siglo XIX , Historia del Siglo XX , Experimentación Humana , Humanos , Inmunidad Innata , Inmunización , India , Mississippi , Parasitemia/terapia , Plasmodium vivax , Vacunas Tifoides-Paratifoides/inmunologíaAsunto(s)
Vacunas contra la Malaria/administración & dosificación , Vacunas contra la Malaria/historia , Malaria/historia , Malaria/prevención & control , Vacunación/historia , Vacunación/estadística & datos numéricos , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Malaria/epidemiologíaRESUMEN
Thirty years ago, the Entomology Branch at the Walter Reed Army Institute of Research (WRAIR) performed the first controlled human malaria infection, in which lab-reared mosquitoes were infected with lab-cultured malaria parasites and allowed to feed on human volunteers. The development of this model was a turning point for pre-erythrocytic malaria vaccine research and, through decades of refinement, has supported 30 years of efficacy testing of a suite of antimalarial vaccines and drugs. In this article, we present a historical overview of the research that enabled the first challenge to occur and the modifications made to the challenge over time, a summary of the 104 challenges performed by WRAIR from the first into 2015, and a prospective look at what the next generation of challenges might entail.
Asunto(s)
Academias e Institutos/historia , Vacunas contra la Malaria , Malaria/prevención & control , Medicina Militar , Proyectos de Investigación , Voluntarios Sanos , Historia del Siglo XX , Experimentación Humana/historia , Humanos , Vacunas contra la Malaria/historia , Vacunas contra la Malaria/uso terapéutico , Medicina Militar/historia , Medicina Militar/métodos , Estados UnidosAsunto(s)
Antimaláricos/uso terapéutico , Investigación Biomédica/métodos , Erradicación de la Enfermedad/métodos , Salud Global , Vacunas contra la Malaria/uso terapéutico , Malaria/prevención & control , Animales , Antimaláricos/historia , Investigación Biomédica/historia , Investigación Biomédica/tendencias , Difusión de Innovaciones , Erradicación de la Enfermedad/historia , Erradicación de la Enfermedad/tendencias , Resistencia a Medicamentos , Salud Global/historia , Salud Global/tendencias , Historia del Siglo XIX , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Malaria/diagnóstico , Malaria/epidemiología , Malaria/historia , Malaria/parasitología , Vacunas contra la Malaria/historia , Factores de Tiempo , Resultado del TratamientoRESUMEN
A vaccine to reduce human suffering caused by malarial parasites has been the holy grail of malaria research. Early studies in the 1940s indicated that attenuated parasites could induce useful immunity. Since that time the genomic revolution led inevitably to the idea of cheap production of safe recombinant vaccines using either expressed protein or DNA vector technologies. It has been difficult to reflect with these 'simple' formulations the efficacies observed with intact parasite immunogens. With the new-found ability to attenuate the parasites by genetic manipulation, ideas have come full circle. Some of the highs and lows of this journey are described from the specific viewpoint of our growing understanding of parasite biology. The objective of many current vaccine initiatives targeting morbidity and mortality is questioned in the light of renewed calls to consider eradication as an objective. The biological rational for approaches to limit parasite transmission are highlighted and their place in future efforts to improve the lives of the 40% of the world's population at risk of the disease is discussed.
Asunto(s)
Vacunas contra la Malaria/historia , Vacunas contra la Malaria/inmunología , Malaria/epidemiología , Malaria/prevención & control , Transmisión de Enfermedad Infecciosa/prevención & control , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Malaria/transmisión , Plasmodium/genética , Vacunas Atenuadas/inmunología , Vacunas de ADN/inmunología , Vacunas de Subunidad/inmunología , Vacunas Sintéticas/inmunologíaRESUMEN
RTS,S is the world's most advanced malaria vaccine candidate and is intended to protect infants and young children living in malaria endemic areas of sub-Saharan Africa against clinical disease caused by Plasmodium falciparum. Recently, a pivotal Phase III efficacy trial of RTS,S began in Africa. The goal of the programme has been to develop a vaccine that will be safe and effective when administered via the Expanded Program for Immunization (EPI) and significantly reduce the risk of clinically important malaria disease during the first years of life. If a similar reduction in the risk of severe malaria and other important co-morbidities associated with malaria infection can be achieved, then the vaccine could become a major new tool for reducing the burden of malaria in sub-Saharan Africa. Encouraging data from the ongoing phase II programme suggest that these goals may indeed be achievable. This review discusses some of the unique challenges that were faced during the development of this vaccine, highlights the complexity of developing new vaccine technologies and illustrates the power of partnerships in the ongoing fight against this killer disease.
Asunto(s)
Enfermedades Endémicas/prevención & control , Vacunas contra la Malaria/historia , Vacunas contra la Malaria/inmunología , Malaria/epidemiología , Malaria/prevención & control , Adyuvantes Inmunológicos/farmacología , África/epidemiología , Ensayos Clínicos Fase II como Asunto , Ensayos Clínicos Fase III como Asunto , Epítopos/inmunología , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Lípido A/análogos & derivados , Lípido A/farmacología , Proteínas Protozoarias/inmunología , Saponinas/farmacologíaAsunto(s)
Antimaláricos/historia , Culicidae/parasitología , Malaria/historia , Plasmodium/fisiología , Animales , Antimaláricos/economía , Antimaláricos/uso terapéutico , Investigación Biomédica/economía , Investigación Biomédica/historia , Eritrocitos/parasitología , Regulación de la Expresión Génica , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Malaria/tratamiento farmacológico , Malaria/parasitología , Vacunas contra la Malaria/economía , Vacunas contra la Malaria/historia , Vacunas contra la Malaria/inmunología , Proteínas Protozoarias/genética , Proteínas Protozoarias/metabolismo , Estados Unidos , Vitaminas/metabolismoRESUMEN
Advances towards protective vaccines against malaria were made feasible by the development of a rodent model of mammalian malaria that allowed production of all stages of the malaria parasite for study. Investigations with sporozoites (the stage transmitted by mosquitoes in their saliva) demonstrated that immunization with radiation-attenuated sporozoites could produce a solid, sterile immunity, first shown in studies with mice and later with human volunteers. Protective immune mechanisms involve anti-sporozoite antibodies that immobilize sporozoites injected into the skin by mosquitoes, followed by CD4+ and CD8+ T-cells acting against liver stage parasites produced by sporozoites that have escaped antibody-based immunity and invaded hepatocytes. Two alternative approaches now being used in human trials are immunization with intact, attenuated sporozoites vs. immunization with "sub-unit" vaccines based on immunogenic components of sporozoites or liver stage parasites. In addition to immunization against these pre-erythrocytic stages, encouraging progress is being made on immunization against blood stage parasites and on immunization for production of transmission-blocking antibodies. There is reason to be optimistic that one or more of the approaches will work on a large scale, and that a multi-stage vaccine may be able to combine several of these approaches in a sequential immunological assault against the malaria parasite as it progresses through its stages.
Asunto(s)
Vacunas contra la Malaria/inmunología , Malaria/prevención & control , Plasmodium/inmunología , Vacunación , Animales , Ensayos Clínicos como Asunto , Modelos Animales de Enfermedad , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Vacunas contra la Malaria/historia , Esporozoítos/inmunologíaRESUMEN
Interest in medicinal plants has increased in recent years. This article examines the history of medicinal plant research through a case study of the London School of Hygiene and Tropical Medicine (LSHTM) over the past 100 years. Papers published by members of the School and documents in the School archives show a fluctuating but continuous interest in plants as sources of medicine. Research interests of individual scientists, changes in the School structure and the changing role of research affected research into medicinal plants at LSHTM. As important were external developments, including the supply of plant resources, especially during wartime, the development of drug-resistance, advances in science and technology, knowledge exchange between both disciplines and cultures, the increased influence of global organizations on policy, as well as pressure groups particularly those involved in conservation. With the revival of interest in plants and the increasing variety of influences on research, it is important to have a better understanding of how debates and subsequent policy impact at the research level, and how research in turn impacts upon policy.
Asunto(s)
Vacunas contra la Malaria/historia , Malaria/tratamiento farmacológico , Plantas Medicinales , Investigación/historia , Medicina Tropical/historia , Antiinfecciosos/uso terapéutico , Artemisia annua , Artemisininas/uso terapéutico , Historia del Siglo XIX , Historia del Siglo XX , Humanos , Londres , Escuelas de Salud Pública/historia , Sesquiterpenos/uso terapéuticoRESUMEN
Following Ronald Ross' demonstration in 1897 that mosquitoes transmit malarial parasites, efforts to control malaria were naturally focussed on attacking the mosquito vector by various measures, mainly directed against the aquatic stages. Although the results were spectacular in some areas, there was a growing realisation that effective control of malaria depended on other factors, including the availability of better drugs than quinine and a greater understanding of the epidemiology of the disease under various environmental conditions. With the discovery of DDT, an all-out effort was made to eradicate malaria by attacking adult mosquitoes. Eradication was not achieved in many countries, mainly because of inadequate health infrastructures. With the emergence of chloroquine-resistant parasites, the search for more effective drug regimens intensified, various drugs and drug combinations were assessed, and methods were developed to monitor and assess degrees of resistance. Since resistance to drugs can develop very quickly, the use of drug combinations, especially those containing artemisinin derivatives, is now recommended. Insecticide-impregnated bednets have become the preferred method of vector control. Although the search for better tools must continue, the events of the past century emphasise the need to strengthen health systems to ensure that they are capable of delivering effective interventions and of assessing their effectiveness in controlling malaria.
Asunto(s)
Antimaláricos/uso terapéutico , Malaria Falciparum/prevención & control , Control de Mosquitos/métodos , Animales , Antimaláricos/historia , Quimioterapia Combinada , Femenino , Salud Global , Historia del Siglo XIX , Historia del Siglo XX , Humanos , Vacunas contra la Malaria/historia , Vacunas contra la Malaria/uso terapéutico , Malaria Falciparum/tratamiento farmacológico , Malaria Falciparum/historia , Masculino , Control de Mosquitos/historiaAsunto(s)
Técnicas de Cultivo/historia , Eritrocitos/parasitología , Malaria Falciparum/historia , Plasmodium falciparum/crecimiento & desarrollo , Animales , Aotus trivirgatus , Células Cultivadas , Medios de Cultivo/historia , Técnicas de Cultivo/métodos , Historia del Siglo XX , Humanos , Vacunas contra la Malaria/historia , Malaria Falciparum/parasitología , Malaria Falciparum/prevención & control , Parasitología/historia , Estados UnidosAsunto(s)
Experimentación Humana/historia , Nacionalsocialismo/historia , Mala Conducta Profesional/historia , Sociedades Científicas , Alemania , Historia del Siglo XX , Experimentación Humana/ética , Humanos , Vacunas contra la Malaria/historia , Apoyo a la Investigación como Asunto/ética , Apoyo a la Investigación como Asunto/historiaRESUMEN
The cluster of seminal microbiological discoveries at the end of the 19th century through to the first quarter of the 20th century gave rise to the expectation that the control of malaria would be by scientific technology (as opposed to the 'brute force' of bonification/massive engeneering works) and that technology would be immunization by a malaria vaccine. Immunology's foundation was in microbiology and the two related disciplines matured concurrently. Immunization with dead or inactivated microorganisms became immunology's strongest arm, affording protection against many major diseases such as smallpox, anthrax, rabies, yellow fever and tetanus. So why not malaria? In the pre-World War II era there were no chemotherapeutic/prophylactic drugs practical for the control of malaria and a vaccine seemed the easy, rational path to that objective. From 1910 to about 1950 there were numerous attempts in humans and primate and avian models to devise a malaria vaccine. However, it soon became apparent that the malaria parasites, because of their complex, stage-specific antigenic identity as well as their relatively poor immunogenicity, would be much more difficult to use as a vaccine than the bacteria or viruses. There were some experimental successes, but none in humans.